Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARAKODA vs FLAGYL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.
Metronidazole, a nitroimidazole antibiotic, enters bacterial cells and is reduced to cytotoxic intermediates that damage DNA and inhibit nucleic acid synthesis, leading to cell death. It is active against anaerobic bacteria and protozoa.
Radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection
Bacterial vaginosis,Trichomoniasis,Amebiasis,Giardiasis,Anaerobic bacterial infections (intra-abdominal, gynecologic, skin and soft tissue, bone and joint, central nervous system, lower respiratory tract, endocarditis, septicemia),Helicobacter pylori eradication (in combination with other agents),Crohn's disease (off-label),Rosacea (topical, off-label oral use is controversial),Prevention of postoperative infection following colorectal surgery
400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).
Metronidazole 500 mg intravenously every 8 hours or 500 mg orally every 8 hours.
Terminal elimination half-life: approximately 14-16 days (range 12-19 days) in healthy adults; this long half-life is due to extensive tissue distribution and slow release from tissues, providing prophylactic coverage for up to 4 weeks after a single dose.
Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged to 7-21 hours in hepatic impairment; no significant change in renal impairment; clinically relevant for dosing interval (usually 8-hourly).
Primarily metabolized by CYP2D6 and monoamine oxidase (MAO). Tafenoquine undergoes extensive metabolism including N-dealkylation and oxidation.
Hepatic metabolism via oxidation and glucuronidation; major metabolites include hydroxy metabolite (active) and acid metabolite. CYP450 enzymes involved (CYP2A6, CYP2C9, CYP3A4).
Biliary/fecal: ~90% unchanged; renal: <1% unchanged (dose-proportional urinary excretion of tafenoquine is minimal, with most eliminated via feces as unchanged drug and minor metabolites).
Renal: 60-80% of dose excreted unchanged in urine; biliary/fecal: 6-15% as metabolites and unchanged drug; enterohepatic circulation contributes to prolonged elimination.
~99.5% bound to human serum albumin (HSA); binding is high and saturable, with unbound fraction slightly increasing at high concentrations.
Less than 20% bound to plasma proteins (primarily albumin).
Apparent Vd: ~2000 L (or ~24-30 L/kg based on 70 kg), indicating extensive tissue distribution (concentrated in red blood cells, liver, lungs, and adipose tissue).
Volume of distribution: 0.6-0.8 L/kg (approximately 40-60 L in adults), indicating extensive tissue penetration; exceeds total body water, consistent with distribution into all tissues including abscess cavities and CNS.
Oral: ~100% (absolute bioavailability not formally determined, but absorption is complete with minimal first-pass metabolism; relative bioavailability is high based on AUC and clinical efficacy).
Oral bioavailability: 80-100% (well absorbed); IV bioavailability: 100% (by definition); Topical: Systemic absorption minimal (<2%).
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
No dose adjustment required for mild to moderate renal impairment (GFR >10 m L/min). For severe renal impairment (GFR <10 m L/min), reduce dose to 500 mg every 12 hours.
Contraindicated in Child-Pugh Class B or C. Use with caution in mild hepatic impairment (Child-Pugh Class A) with no dose adjustment.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (e.g., 250 mg every 8 hours). Child-Pugh C: reduce dose to 250 mg every 12 hours.
Safety and efficacy not established in pediatric patients (<18 years).
15-50 mg/kg/day intravenously or orally divided every 8 hours, depending on infection type and severity. Maximum 4 g/day.
No specific dose adjustment; use with monitoring for renal function due to age-related decline and potential for increased adverse effects.
Monitor renal function; same dosing as adults unless severe renal impairment (Cr Cl <10 m L/min) requires dose reduction to 500 mg every 12 hours.
ARAKODA can cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD testing must be performed before prescribing due to risk of hemolytic anemia.
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. Chromosomal aberrations have been reported in patients with Crohn's disease and other conditions. Use should be reserved for approved indications only.
Hemolytic anemia in G6PD-deficient patients (contraindicated in G6PD deficiency without prior testing),Methemoglobinemia (rare, monitor for cyanosis and dyspnea),Psychiatric effects including anxiety, depression, and insomnia,Hepatotoxicity (rare, monitor liver function),Use in pregnancy: not recommended (risk of hemolysis in G6PD-deficient fetus),Lactation: avoid if breastfeeding infant is G6PD deficient
Carcinogenicity risk (see black box warning),Neurologic effects: peripheral neuropathy, seizures, encephalopathy; discontinue if abnormal neurologic signs occur,Hematologic effects: leukopenia, neutropenia; monitor CBC,Hepatic impairment: dosage adjustment recommended,Metronidazole may cause metallic taste, dark urine, and disulfiram-like reaction with alcohol,Prolonged use may result in superinfection (e.g., C. difficile diarrhea),Potential for ethylene glycol toxicity if administered with propylene glycol-containing solutions
G6PD deficiency (without confirmed normal G6PD activity),Known hypersensitivity to tafenoquine or any 8-aminoquinoline,Use in children <16 years (safety not established),Severe renal impairment (e GFR <30 m L/min),Lactation in infants with G6PD deficiency or unknown G6PD status
Hypersensitivity to metronidazole or other nitroimidazole derivatives,First trimester of pregnancy (avoid; use during later trimesters only if clearly needed),Breastfeeding (discontinue drug or bottle-feed; excreted in breast milk),History of blood dyscrasias,Concurrent use of disulfiram (psychotic reactions may occur; wait at least 2 weeks after disulfiram),Concurrent use of propylene glycol-containing IV formulations in neonates or patients with renal impairment
Take with a fatty meal to increase absorption. No specific dietary restrictions. Avoid grapefruit juice as it may alter metabolism.
Avoid alcohol and any products containing ethanol (including certain mouthwashes, cough syrups, and fermented foods) during therapy and for at least 48 hours after last dose. No other food restrictions.
FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.
Flagyl (metronidazole) crosses the placenta. In the first trimester, use is generally avoided due to theoretical risk of teratogenicity, but data from large cohort studies do not show a significant increase in major malformations (risk category B). In the second and third trimesters, no fetal harm has been demonstrated; however, use only if clearly needed. High doses associated with fetal toxicity in animals.
Excreted in human milk; M/P ratio unknown. Potential for adverse effects in infant; use caution, consider discontinuing breastfeeding.
Metronidazole is excreted into breast milk with an M/P ratio of approximately 0.9-1.5. After a single 2 g oral dose, peak milk concentration ~10-20 mcg/m L. The American Academy of Pediatrics considers it compatible with breastfeeding, but because of potential mutagenicity, avoid high doses (e.g., 2 g single dose) for 12-24 hours; resume breastfeeding after 2-3 half-lives. Lower doses (250-500 mg) are considered safe.
No established dose adjustments; pharmacokinetic changes in pregnancy may require monitoring drug levels and clinical response.
No specific dose adjustment for pregnancy. However, due to increased plasma volume and renal clearance, standard doses (e.g., 500 mg IV every 6-8 hours) may require monitoring for efficacy. Oral bioavailability unchanged. Use with caution if hepatic impairment.
ARAKODA (tafenoquine) is indicated for radical cure of Plasmodium vivax malaria. Assess G6PD status before prescribing; contraindicated in G6PD-deficient patients due to hemolytic anemia risk. Monitor for methemoglobinemia. Avoid use in pregnancy/lactation. Take with food to enhance absorption.
Flagyl (metronidazole) is first-line for anaerobic infections and bacterial vaginosis. It can cause a disulfiram-like reaction with alcohol; avoid ethanol during therapy and for 48 hours after last dose. Monitor for peripheral neuropathy with prolonged use. IV formulation is highly irritating; avoid extravasation. Use with caution in hepatic impairment; dose reduction may be needed. Metallic taste is common but benign.
Take with food to improve absorption.,You must be tested for G6PD deficiency before starting this medication.,Report any signs of anemia, dark urine, or yellowing of eyes/skin.,Avoid use during pregnancy or breastfeeding.,Do not drive if you experience dizziness or blurred vision.
Do not drink alcohol or use products containing alcohol during treatment and for 48 hours after the last dose to avoid severe nausea, vomiting, and flushing.,Take with food to reduce gastrointestinal upset.,Complete the full course even if symptoms improve to prevent resistance.,May cause a metallic taste, which is temporary.,Avoid sexual intercourse or use condoms during treatment for trichomoniasis; partners may need treatment.,Notify doctor if you experience numbness, tingling, or pain in hands/feet.,For vaginal gel, avoid alcohol-containing products (e.g., douches) for 24 hours after use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARAKODA vs FLAGYL, answered by our medical review team.
ARAKODA is a Antimalarial that works by ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.. FLAGYL is a Nitroimidazole Antibiotic that works by Metronidazole, a nitroimidazole antibiotic, enters bacterial cells and is reduced to cytotoxic intermediates that damage DNA and inhibit nucleic acid synthesis, leading to cell death. It is active against anaerobic bacteria and protozoa.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARAKODA and FLAGYL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARAKODA is: 400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).. The standard adult dose of FLAGYL is: Metronidazole 500 mg intravenously every 8 hours or 500 mg orally every 8 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARAKODA and FLAGYL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARAKODA is classified as Category C. FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.. FLAGYL is classified as Category C. Flagyl (metronidazole) crosses the placenta. In the first trimester, use is generally avoided due to theoretical risk of teratogenicity, but data from large cohort studies do not s. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.